Publication Date
1-1-2022
Journal
Frontiers in Global Women's Health
DOI
10.3389/fgwh.2022.856316
PMID
35449709
PMCID
PMC9016174
PubMedCentral® Posted Date
4-5-2022
PubMedCentral® Full Text Version
Post-print
Published Open-Access
yes
Keywords
endometriosis, angiogenesis, estrogen receptors, vascular endothelial growth factor, anti-angiogenic therapy
Abstract
Endometriosis is a known estrogen-dependent inflammatory disease affecting reproductive-aged women. Common symptoms include pelvic pain, dysmenorrhea, dyspareunia, heavy menstrual bleeding, and infertility. The exact etiology of endometriosis is largely unknown, and, thus, the diagnosis and treatment of endometriosis are challenging. A complex interplay of many molecular mechanisms is thought to aid in the progression of endometriosis, most notably angiogenesis. This mini-review examines our current knowledge of the molecular etiology of endometriosis-associated angiogenesis and discusses anti-angiogenic therapy, in the blockade of endometriosis-associated angiogenesis, as potential non-hormonal therapy for the treatment of endometriosis.
Included in
Biological Phenomena, Cell Phenomena, and Immunity Commons, Life Sciences Commons, Medical Cell Biology Commons, Medical Microbiology Commons, Medical Molecular Biology Commons, Obstetrics and Gynecology Commons, Women's Health Commons